R. Alan B. Ezekowitz

Co-Founder at Vividion Therapeutics, Inc.

R. Alan B. Ezekowitz

R. Alan B. Ezekowitz

Co-Founder at Vividion Therapeutics, Inc.

Overview
Career Highlights

Vividion Therapeutics, Inc.
Abide Therapeutics, Inc.
Azanta Danmark A/S

RelSci Relationships

2204

Number of Boards

14

Birthday

1954

Age

64

Relationships
RelSci Relationships are individuals R. Alan B. Ezekowitz likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Cardinal Partners

Relationship likelihood: Strong

Chairman, Department of Chemical Physiology at The Scripps Research Institute

Relationship likelihood: Strong

Co-Founder at REPLIGEN Corp.

Relationship likelihood: Strong

Co-Founder at Abide Therapeutics, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Kallyope, Inc.

Relationship likelihood: Strong

Senior Vice President & Chief Innovation Officer at The Brigham & Women's Hospital, Inc.

Relationship likelihood: Strong

Venture Partner at ARCH Venture Partners

Relationship likelihood: Strong

Co-Founder at Vividion Therapeutics, Inc.

Relationship likelihood: Strong

Chairman at Celgene Research & Development LLC

Relationship likelihood: Strong

Co-Founder at Cardinal Partners

Relationship likelihood: Strong

Paths to R. Alan B. Ezekowitz
Potential Connections via
Relationship Science
You
R. Alan B. Ezekowitz
Co-Founder at Vividion Therapeutics, Inc.
Education
Doctor of Philosophy

Oxford is a collegiate university, consisting of the central University and colleges. The central University is composed of academic departments and research centres, administrative departments, libraries and museums. The 38 colleges are self-governing and financially independent institutions, which are related to the central University in a federal system. There are also six permanent private halls, which were founded by different Christian denominations and which still retain their Christian character.

Career History
Co-Founder
2014 - Current

Vividion Therapeutics, Inc. operates as a biotechnology company. It focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke and Alan Ezekowitz in 2014 and is headquartered in Princeton, NJ.

Co-Founder
2011 - Current

Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.

Advisor
2011 - Current

Cardinal Partners focuses exclusively on healthcare investments including the life sciences, medical devices and healthcare information technology. The firm specializes in early-stage financing rounds, usually as the lead investor in the initial financing round of a growth company. Investments generally range from $6 million to $12 million per company. Cardinal Partners targets companies that: (1) operate in large or fast-growing markets (2) have a strong CEO, founder, team or scientist (3) possess a proprietary intellectual asset or novel technology and (4) have a well-defined business model.

Boards & Committees
Member, Board of Directors
2017 - Current

Fulcrum Therapeutics, Inc. develops new medicines. It focus on unlocking gene control mechanisms to develop small molecule therapies. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie Lee and Bradley E. Bernstein and is headquartered in Cambridge, MA.

Non-Executive Director
2013 - Current

Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing in 1997 and is headquartered in Abingdon, the United Kingdom.

Member, Advisory Board
Current

Qpid Health, Inc. provides health record acceleration software and intelligence solutions. It develops clinical insights software for use by hospitals and medical groups. The firm’s QPID solution uses natural language processing and proprietary tools to improve how clinical and administrative users can have access to information stored in electronic health records. The company was founded by Michael Zalis and Mitchell Harris in 2011 and is headquartered in Boston, MA.

Chairman
Prior

Massachusetts General Hospital Cancer Center operates as cancer treatment center. The company was founded by John Warren in 1811 and is headquartered in Boston, MA.

Member, Board of Directors
Prior

Children's Hospital Corp. provides health care services that includes acupuncture, cardiac anesthesia, pediatric cataract, andrology program, atopic dermatits center, augmentative communication program, exercise physiology, endodontics, and many more. The company was founded in 1869 and is headquartered in Boston, MA.

Director
Prior

Partners HealthCare System, Inc. provides patient care, research, teaching and community services. It offers community and specialty hospitals, physician network, community health centers, home care and other health-related entities. The firm also sponsors research programs and community health outreach programs. The company was founded in 1994 and is headquartered in Boston, MA.

Transactions
Details Hidden

Abide Therapeutics, Inc. raised money in a private placement transaction

Investments
Details Hidden

Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.

Details Hidden

Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark.